| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $11.9M | -5.5% | +1218.0% |
| SG&A Expense | $3.6M | -3.4% | -4.6% |
| Operating Income | -$15.5M | +5.0% | -232.4% |
| Net Income | -$14.7M | +4.5% | -298.1% |
| EPS (Basic) | -$1.09 | +4.4% | +0.9% |
| EPS (Diluted) | -$1.09 | +4.4% | +0.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $70.3M | -15.6% | +15.9% |
| Current Assets | $71.5M | -15.4% | -7.1% |
| Total Assets | $72.8M | -15.4% | -6.2% |
| Current Liabilities | $6.2M | -17.8% | +92.3% |
| Total Liabilities | $6.4M | -18.9% | +76.6% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$40.3M | — | — |
| Capital Expenditures | $37K | — | — |
| Investing Cash Flow | -$37K | — | — |
| Financing Cash Flow | -$77K | — | — |
| Free Cash Flow | -$40.4M | — | — |
| $66.4M |
| -15.0% |
| -10.3% |